Mo is CEO of hVIVO with over 25 years of experience in clinical research and the CRO industry. Mo has worked as a consultant assisting CROs to develop growth strategies and helping prepare companies for future expansion, both organic and through M&A activity. In addition, Mo worked with Private Equity firms providing insight in identifying potential targets and conducting due diligence in preparation for M&A activity. Prior to this Mo had a variety of senior roles at Pharm-Olam where he played a pivotal role in growing a small niche clinical monitoring business to a global full-service CRO with offices across all continents. In his time at Pharm-Olam Mo had leading roles in Clinical Operations, Project Management, Business Development and Executive Management functions. As a key member of the Executive Team Mo participated in the successful sale of the company in 2017, delivering substantial returns to its shareholders. Prior to this he worked at Innovex and Quintiles (IQVIA).

Stephen is a chartered accountant with over 25 years of experience in a range of leadership positions in industries covering publishing, technology, exhibitions, and clinical research. The roles have covered both small to large international listed businesses, providing strong technical and commercial experience. Prior to joining hVIVO, he worked in Thomson Reuters for eleven years in various senior roles. He did his articles with Deloitte following the completion of an Honours Degree in Bachelor of Commerce and a Bachelor’s Degree in Accounting and Finance from the University of Cape Town.

Andrew first studied as a virologist at the University of Warwick before then furthering his education with postgraduate studies in influenza replication at Oxford University. Since then he has applied his scientific knowledge in a commercial setting. After working as part of a multidisciplinary R&D team developing nuclear medicine research tools at GE Healthcare, he then returned to the field of virology to work for hVIVO, an industry-leading service provider of human viral challenge studies (controlled human infection studies). Andrew is now considered an expert in human viral challenge studies having played key roles in the development of influenza, RSV and HRV models at hVIVO. He has overseen the design and conduct of numerous antiviral and vaccine product efficacy studies and now works as Chief Scientific Officer, leading scientific strategy for the company as well as providing consultancy both internally and externally to hVIVO’s clients and collaborators on challenge study design and data interpretation. In addition, he was PI on a recent successfully completed DARPA-sponsored research project to utilise the challenge model to identity human biomarkers and algorithms prognostic of influenza contagiousness.

Adam French brings over 18 years’ experience working in a number of roles in the Pharmaceutical and CRO industry, including project management and laboratory leadership. His love for biological sciences started from a young age and was cemented after graduating from Anglia Ruskin University in Biomedical Sciences whilst working in the labs at Huntingdon Life Sciences. There his skills for operational leadership were honed whilst working on global business change and strategy projects, before he moved on to more senior roles elsewhere. Adam joined hVIVO in 2014, where he has implemented a number of productivity and growth improvements, with a focus on operational delivery, business growth and personnel development.

Mariya has worked for hVIVO since 2014 in various roles including Viral Challenge Physician, Senior Physician/ Principal Investigator, Associate Medical Director and has been appointed in March 2021 as Medical Director. Since qualification in 1996 at the Medical University, Sofia, Bulgaria Mariya specialized in General (Internal) Medicine. Mariya have wide experience in oncology, hematology, rheumatology, gastroenterology, endocrinology and Chronic & Preventative Care; both in Bulgaria and the UK. She is on the GMC Specialist Register for General (Internal) Medicine, and has a current ALS certificate. Mariya is an experienced pharmaceutical physician; this expertise extends to RSV challenges, Influenza, HRV and SARS-CoV-2. As PI, Mariya has been responsible for many clinical trials including RSV, SARS-CoV-2 characterisation and vaccine trials. She has developed and overseen clinical development for clients including safety and medical monitoring. She also regularly trains, supervises and supports staff and investigators.

Marianne joined hVIVO in 2012 and has held various positions within the laboratory team. She is currently Associate Director, Laboratory Operations. Over her time at hVIVO, she has been involved in key company projects including setting up the site and study for the first SARS-CoV-2 human challenge model in the world. Marianne heads up the laboratory operational delivery. She is responsible for laboratory management, the day-to-day delivery of studies, and line management of the operational teams. Prior to joining hVIVO, she worked for Boehringer Ingelheim, focusing on veterinary product quality control, particularly on virus inactivation in final products. Marianne studied at the University of Lyon (France), and gained a Degree in Biochemistry, followed by a Masters in Biotechnology and Biochemical Engineering.

Alison is an experienced scientist, project manager, and operational lead with over 20 years working in laboratory and clinical research having graduated from the University of Nottingham in 2002. Alison started her career at hVIVO (formally Retroscreen Virology) as a Research Scientist under Professor John Oxford, leading multiple clinical and preclinical studies and programs of work to GLP, GCP, ICH, and FDA quality standards. During this time Alison gained a wealth of experience in regulatory, multi-site, vendor management, and global field trial support, involving both hazard group 2 and 3 pathogens, including being the analytical lead for the world’s first human SARS-CoV-2 human challenge study. Alison has additionally worked cross functionally with other departments spending time as a clinical project manager and leading some key hVIVO GMP challenge agent development programs. As the Laboratory Director, Alison oversees the operational delivery and project management of hVIVO’s specialised virology laboratory studies and the development & validation of new assays and technologies within hLAB. Alison is currently leading the expansion of laboratory services, identifying growth opportunities, and implementing innovation processes.